Stock CLDI CALIDI BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Calidi Biotherapeutics, Inc.

Equities

CLDI

US3207031010

Market Closed - Nyse
Other stock markets
 16:00:00 2024-05-13 EDT 		5-day change 1st Jan Change
0.2222 USD -5.85% Intraday chart for Calidi Biotherapeutics, Inc. +5.81% -85.28%
04-16 Calidi Biotherapeutics Prices $6.1 Million Offering MT
03-21 H.C. Wainwright Lowers Price Target on Calidi Biotherapeutics to $2 From $11, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
BU
Join Calidi Biotherapeutics Exclusive Live Investor Webinar and Q&A Session on April 24
AQ
Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24
BU
Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
BU
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company's Novel Immunotherapies at the AACR Annual Meeting 2024
AQ
Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024
BU
Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results
BU
Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer
BU
Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference
BU
Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board
BU
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPre to its Board of Directors
AQ
Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit
BU
Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors
BU
Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones
BU
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result
AQ
Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results
BU
Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)
BU
Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment
BU
Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CLDI Stock
  4. News Calidi Biotherapeutics, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW